Postoperative Stimulated Thyroglobulin Level and Recurrence Risk Stratification in Differentiated Thyroid Cancer

Xue Yang1, Jun Liang2, Tian-Jun Li2, Ke Yang1, Dong-Quan Liang3, Zhuang Yu2, Yan-Song Lin1

1Department of Nuclear Medicine, Peking Union Medical College Hospital, Beijing 100730, China
2Department of Oncology, Affiliated Hospital of Qingdao University, Qingdao, Shandong 266000, China
3Grade 12, Beijing Hui Jia (IB) Private School, Beijing 102200, China

Abstract

Background: Postoperative preablative stimulated thyroglobulin (ps-Tg) has been evaluated in predicting prognosis and success of ablation regarding differentiated thyroid cancer (DTC); however, its relationship with recurrence risk and radioiodine decision-making remains uncertain, especially in Chinese DTC patients. We aimed to evaluate the association between ps-Tg and recurrence risk stratification in DTC, to provide incremental values for ps-Tg in postoperative assessment and radioiodine management.

Methods: Seven hundred and seven patients with DTC were included; low-risk (L; n = 90), intermediate-risk (I; n = 283), and high-risk (H; n = 334, 117 with distant metastasis [M1]) patients were divided according to recurrence risk stratification. The M1 group was further analyzed regarding evidence of metastasis. Cut-off values of ps-Tg were obtained using receiver operating characteristic analysis.

Results: Patients with more advanced disease at initial risk stratification were more likely to have higher ps-Tg levels (I vs. L: P < 0.05; H vs. I: P < 0.001; H vs. L: P < 0.001). The corresponding cut-off value of ps-Tg for distinguishing sensitivity and specificity in each of the two groups was 2.95 ng/ml (I vs. L: 61.5%, 63.3%), 29.5 ng/ml (H vs. I: 41.9%, 92.6%), 47.1 ng/ml (M1 vs. M0 in the H group: 79.5%, 88.9%) and 47.1 ng/ml (M1 vs. M0 in all patients: 79.5%, 93.7%). With the cut-off value at 47.1 ng/ml, ps-Tg was the only factor that could be used to identify distant metastases, and consequently if measured before radioiodine therapy would prevent 10.26% of patients with M1 from undertreatment.

Conclusions: Ps-Tg, as an ongoing reassessment marker, favors differential recurrence risk grading and provides incremental values for radioiodine treatment decision-making.

Key words: Ablation; Differentiated Thyroid Carcinoma; Radioiodine Therapy; Recurrence Risk Stratification; Thyroglobulin

Introduction

Differentiated thyroid carcinoma (DTC) accounts for 90% of all thyroid cancers, including papillary thyroid carcinoma (PTC), follicular thyroid carcinoma (FTC) and Hürthle carcinoma. Surgery, selective postoperative radioiodine and thyroid stimulating hormone (TSH) suppressive therapy are the primary treatment modalities for DTC. Although the overall treatment outcome regarding DTC is excellent and the 10-year survival rate is about 90%,1,2 the rate of persistent or recurrent cases is 23–30%.3,4,5 this indicates that the risk of recurrence cannot be underestimated. In 2009, the American Thyroid Association (ATA) published Management Guidelines for Patients with Thyroid Nodules and DTC for the improved assessment of recurrence and mortality, and graded DTC patients into three categories (low, intermediate and high) in terms of the risk of recurrence. Shortly afterward, Tuttle et al.6 confirmed that this recurrence staging system could effectively predict the risk of recurrence and persistent disease. This recurrence risk stratification system can provide promising guidance concerning the initial postoperative management of DTC, but it can also give rise to controversy. The prognostic factors described in this system include incomplete tumor resection, aggressive histology subtypes, tumor invasion, cervical lymph node metastasis, distant metastasis and I-131 uptake outside the thyroid bed on whole-body scans (WBSs) undertaken after radioiodine remnant ablation. Apart from the aforementioned points, the discrepancy between the actual thyroglobulin (Tg) level and the posttreatment imaging findings has also been mentioned as a weighing factor for high recurrence risk in the ATA guidelines, based on its predictive value for both ablation success and prognosis.6,7 Nevertheless, the specific value of postoperative Tg in indicating a high recurrence risk remains to be established. In addition, some researchers...
have argued that the preablative stimulated Tg (ps-Tg) level may be influenced by postoperative thyroid tissue remnants,\(^6\) and that it would take at least 1-year for Tg to become undetectable.\(^{12-15}\) Thus, the specific value and the significance of ps-Tg regarding decision-making require further investigation.

At present in China, surgical techniques such as cervical lymph node dissection are incongruently assigned to patients, and the time interval between surgery and treatment using nuclear medicine varies from a few days to a few years. Therefore, a marker that could reflect ongoing disease status is urgently needed, rather than static pathological findings during surgery. There is evidence to indicate that ps-Tg measured just before radioiodine treatment may have a role as such a marker.\(^{8,9,14,15}\)

To date, very few data regarding the relationship between ps-Tg and the three recurrence risk categories of ATA have been reported. In this study, we introduced the ps-Tg level into ongoing postoperative reassessment to explore the correlation between ps-Tg level and ATA recurrence risk stratification; the objective was to provide evidence-based support for Chinese patients for the role of ps-Tg in postoperative reassessment and radioiodine treatment decision-making.

**Methods**

The study was approved by the Ethics Committee of Peking Union Medical College Hospital.

**Patients**

In this retrospective study, 985 patients with DTC received total thyroidectomy followed by radioiodine treatment from 2007 to 2013. A total 278 of these patients were excluded from the study; 177 had high Tg antibody (TgAb) levels (>46 IU/ml)\(^6\) and the other 101 had missing data regarding ps-Tg or TgAb levels. Therefore, 707 patients were finally enrolled in the study, including 482 females and 225 males with a mean age of 42.7 (range, 4–77) years. Histologically, 685 patients were diagnosed with PTC and 22 with FTC. All patients underwent total thyroidectomy performed by experienced surgeons, with no macroscopic thyroid remnants remaining; seven of these patients with papillary thyroid microcarcinoma (tumor size ≤1 cm) did not undergo cervical lymph node dissection. Patients received I-131 at a dose that varied from 30 mCi (1.1 GBq) to 200 mCi (7.4 GBq) according to their ATA recurrence risk stratification\(^6\) within 3 months after surgery; they underwent levothyroxine (LT4) withdrawal or no replacement treatment and a low-iodine diet for at least 2–6 weeks when serum TSH levels were >30 μIU/ml.

**Measurements and tests**

Levels of ps-Tg, TgAb and TSH were measured before the first I-131 remnant ablation after thyroxine hormone withdrawal, and the TSH level had risen (TSH > 30 μIU/ml). Tg and TgAb levels were determined using electrochemiluminescence immunoassay (Roche Diagnostics GmbH, Mannheim, Germany), and the TSH level was determined using chemiluminescence immunoassay (Siemens Healthcare Diagnostics Inc., New York, NY, USA) in the same laboratory. Patient characteristics were compiled including age, sex, histology subtypes, tumor invasion, cervical lymph node metastasis, distant metastasis, remnant uptake on I-131-WBS, TSH, and ps-Tg and TgAb levels. Patients were divided into three groups according to the ATA recurrence risk stratification:\(^6\) Low-risk (L; n = 90), intermediate-risk (I; n = 283) and high-risk (H; n = 334). The H group was further subdivided into two subgroups, one with distant metastasis (M1; n = 117) and the other without distant metastasis (M0; n = 217). Additionally, while assigning patients to H group, we did not take the ps-Tg level into account, because the predictive cut-off value was not specified in the ATA Guidelines.\(^9\) Patients with at least one of the following characteristics, according to *ATA and the National Comprehensive Cancer Network guidelines*\(^6,17-19\) were considered for subsequent radioiodine therapy: Male; age >45 years; tumor size >1 cm; multiple lesions (>1 lesion); and molecular characteristics such as the BRAFV600E mutation. Because increased TSH stimulates ps-Tg during the LT4 withdrawal period, indicating that Tg release is TSH-dependent,\(^20-22\) we introduced the parameter ps-Tg/TSH. The associations between ps-Tg, ps-Tg/TSH and three recurrence risk groups were analyzed. The M1 group was further analyzed in terms of metastatic evidence such as chest computed tomography, bone scan, postradioiodine-therapy WBS (RxWBS) combined with a suspicious high ps-Tg level.

**Statistical analysis**

Rank sum and *F* tests were used for the comparison of ps-Tg and ps-Tg/TSH values. The Kruskal-Wallis and *F* tests were used for comparisons among the three groups; the Mann-Whitney *U* and *F* tests were used to compare any two groups. The most sensitive and specific ps-Tg values for distinguishing each of the two group comparisons were obtained using receiver operating characteristic (ROC) curves. Gender (female or male), age (<45 years or ≥45 years), tumor size (maximum diameter ≤1 cm or >1 cm), multifocality (single lesion or multiple lesions) and ps-Tg level (<corresponding cut-off value or ≥corresponding cut-off value) were involved as independent variables of recurrence and distant metastasis. These factors were further analyzed using logistic regression analysis to identify if ps-Tg was an independent predictive factor for discerning different recurrence risk groups, and if distant metastases existed. *P* < 0.05 was considered as statistically significant. All of these statistical analyses were performed using SPSS software (Version 17.0, Inc., Chicago, IL, USA) and R project (Version 2.15.1).

**Results**

**Comparisons of preablative stimulated thyroglobulin in different recurrence risk groups**

The descriptive characteristics of the 707 patients are given in Table 1. The ratio of females to males was 2.14:1, 96.89%
of patients had PTC and the preablative TSH level was 91.36 ± 35.57 μU/ml. Analysis of the three risk classification groups of L, I and H revealed that the more advanced the stratification, the greater the likelihood of a higher ps-Tg level. This trend could also be seen when comparing the L, I and H groups with the M0 and M1 groups [Figure 1]. Especially, in the case of the H group, it was found that the subgroup with distant metastasis was accompanied by the highest ps-Tg level [Figure 1].

The mean ps-Tg level for the L, I and H groups was 5.278, 11.588 and 159.939 ng/ml, respectively. The corresponding standard deviation varied greatly between the three recurrence risk groups [Table 2]. The median ps-Tg level for the L, I and H groups was 1.7, 4.4 and 14.7 ng/ml, respectively, and the corresponding 25–75% quartile was 0.3–5.4 ng/ml, 1.2–13.3 ng/ml and 2.2–137.2 ng/ml, respectively [Table 2].

When comparing the ps-Tg level among the three recurrence risk groups, significant differences could be found both using the F test ($P < 0.001$; $F = 48.254$) and the Kruskal-Wallis test ($P < 0.001$; $\chi^2 = 61.388$) [Table 2]. Further comparisons between groups also revealed a similar trend using both the $F$ test ($L$ vs. $I$, $P = 0.014$, $F = 6.107$; $H$ vs. $I$, $P < 0.001$, $F = 24.905$; $H$ vs. $L$, $P < 0.001$, $F = 71.783$) and the Mann–Whitney U-test ($L$ vs. $I$, $P < 0.001$, $z = −3.986$; $H$ vs. $I$, $P < 0.001$, $z = −7.367$; $H$ vs. $L$, $P < 0.001$, $z = −7.645$) [Table 2].

**Receiver operating characteristic analysis of preablative stimulated thyroglobulin level**

Receiver operating characteristic curves used for evaluating the most sensitive and specific ps-Tg values for distinguishing each of the two group comparisons are shown in Figure 2. The area under the ROC curve for the ps-Tg level used for distinguishing the groups was 0.631 (L vs. I), 0.668 (I vs. H), 0.913 (M0 vs. M1 in the H group) and 0.931 (M0 vs. M1 in all patients). Two definite cut-off values of ps-Tg, namely 2.95 ng/ml and 29.5 ng/ml, were obtained for differentiating the L from the I group as well as the I from the H group; these values might be used as indicators to distinguish each recurrence risk group [Figure 2]. In addition, when only

| Table 1: Characteristics of study subjects |
|-----------------|-----------------|-----------------|-----------------|-----------------|
| **Characteristics** | **Low risk** | **Intermediate risk** | **High risk** | **Total** |
| **Number** | | | | 707 |
| **Gender, n (%)** | | | | |
| Male | 90 (21.11) | 94 (33.22) | 112 (33.53) | 225 (31.82) |
| Female | 19 (78.89) | 189 (66.78) | 222 (66.47) | 482 (68.18) |
| **Age** | | | | |
| Mean ± SD (years) | 45.63 ± 12.14 | 40.23 ± 11.72 | 44.09 ± 13.69 | 42.74 ± 12.89 |
| **Histologic subtypes, n (%)** | | | | |
| Papillary | 90 (100) | 277 (97.88) | 318 (95.21) | 685 (96.89) |
| Follicular | 0 (0) | 6 (2.12) | 16 (4.79) | 22 (3.11) |
| **TSH** | | | | |
| Mean ± SD (μIU/ml) | 85.85 ± 28.50 | 92.02 ± 35.33 | 92.28 ± 37.40 | 91.36 ± 35.57 |
| **Surgical methods, n (%)** | | | | |
| Total thyroidectomy + cervical lymph node dissection | 83 (92.22) | 283 (100) | 334 (100) | 700 (99.01) |
| Total thyroidectomy only | 7 (7.78) | 0 (0) | 0 (0) | 7 (0.99) |

$n$: Number of patients; SD: Standard deviation; TSH: Thyroid stimulating hormone.
comparing patients in the H group, the cut-off ps-Tg value in discriminating M1 from M0 was 47.1 ng/ml (sensitivity: 79.5%; specificity: 88.9%). In addition, when dividing all patients into two groups according to whether or not distant metastasis was present, the specificity of the cut-off ps-Tg value (47.1 ng/ml; sensitivity: 79.5%; specificity: 93.7%) became even higher than that in high-risk patients [Figure 2].

Table 2: Comparison of ps-Tg and ps-Tg/TSH among different recurrence risk groups

| Factors             | Low risk         | Intermediate risk | High risk        | F test  | Kruskal-Wallis test |
|---------------------|------------------|-------------------|------------------|---------|---------------------|
| ps-Tg (ng/ml)       |                  |                   |                  |         |                     |
| Mean ± SD           | 5.278 ± 8.987    | 11.588 ± 23.667   | 159.939 ± 293.717| 48.254* | 61.388*             |
| Median              | 1.7              | 4.4               | 14.7             |         |                     |
| ps-Tg/TSH (ng/μIU)  |                  |                   |                  |         |                     |
| Mean ± SD           | 0.061 ± 0.097    | 0.171 ± 0.426     | 2.423 ± 5.611    | 30.582* | 50.010*             |
| Median              | 0.022            | 0.051             | 0.195            |         |                     |

*P<0.001, P values were all <0.05 in further pairwise comparisons of ps-Tg and ps-Tg/TSH values among the three risk groups using the F test; †P<0.001, P values were all <0.05 in further pairwise comparisons of ps-Tg and ps-Tg/TSH values among the three risk groups using the Mann-Whitney U-test. SD: Standard deviation; ps-Tg: Preablative stimulated thyroglobulin; ps-Tg/TSH: Preablative stimulated thyroglobulin/thyroid stimulating hormone.

Figure 2: ROC of serum ps-Tg and ps-Tg/TSH level. (a) ROC in distinguishing low from intermediate recurrence risk groups; (b) ROC in distinguishing intermediate from high recurrence risk groups; (c) ROC in distinguishing M1 from M0 in the high recurrence risk group; (d) ROC in distinguishing M1 from M0 in all patients. ROC: Receiver operating characteristic curve; AUC: Area under the curve; ps-Tg: Preablative stimulated thyroglobulin; ps-Tg/TSH: Preablative stimulated thyroglobulin/thyroid stimulating hormone; M1: Distant metastasis; M0: No distant metastasis.

Univariate and multivariate logistic analyses

Gender (female or male), age (<45 years, or ≥45 years), tumor size (maximum diameter ≤1 cm or >1 cm), multifocality (single lesion or multiple lesions) and ps-Tg level (<corresponding cut-off value or ≥corresponding cut-off value) were analyzed as independent variables using logistic regression analysis.
In univariate logistic regression analysis, the role of ps-Tg was significant in distinguishing between I and L groups (odds ratio \( OR \): 2.757; 95% confidence interval \([CI]\): 1.687–4.506; \( P < 0.001 \)), as well as between H and I groups (\( OR \): 9.490; 95% \( CI \): 5.733–15.707; \( P < 0.001 \)). Even higher OR values could be obtained in comparing both the M1 and M0 subgroups in the H group (\( OR \): 31.161; 95% \( CI \): 16.805–57.784; \( P < 0.001 \)) and between the M1 and M0 subgroup in all patients (\( OR \): 57.916; 95% \( CI \): 33.125–101.260; \( P < 0.001 \)), which further confirmed the high accuracy and predictive value of ps-Tg [Table 3].

In further multivariate logistic regression analyses, except for the interference of other factors, ps-Tg was confirmed to be an independent prediction factor for differentiating the various groups (H vs. I, \( OR \): 8.021, 95% \( CI \): 4.771–13.486, \( P < 0.001 \); M1 vs. M0 in the H group, \( OR \): 31.977, 95% \( CI \): 16.575–61.688, \( P < 0.001 \); M1 vs. M0 in all study patients, \( OR \): 52.141, 95% \( CI \): 28.581–95.122, \( P < 0.001 \)). In spite of relative low efficacy (area under the curve, 0.631) of ps-Tg in discerning the L and I groups using ROC analysis, the \( OR \) (\( OR \): 2.541, 95% \( CI \): 1.529–4.223, \( P < 0.001 \)) was high enough to validate that ps-Tg could be defined as an independent predictive factor [Table 3].

Table 3: Logistic regression analysis of recurrence risk and distant metastasis status according to clinicopathologic factors

| Factors | Univariate logistic regression | Multivariate logistic regression |
|---------|-------------------------------|---------------------------------|
|         | \( OR \) (95% \( CI \))       | \( P \)                         | \( OR \) (95% \( CI \))       | \( P \) |
| Low risk versus intermediate risk | | | | |
| ps-Tg* | 2.757 (1.687–4.506)            | \(< 0.001 \)                    | 2.541 (1.529–4.223)           | \(< 0.001 \) |
| Gender | 1.859 (1.058–3.265)            | 0.031                          | 1.587 (0.882–2.853)           | 0.123 |
| Age*   | 0.464 (0.286–0.750)            | 0.002                          | 0.490 (0.297–0.810)           | 0.005 |
| Tumor size* | 1.479 (0.916–2.388)       | 0.109                          | 1.210 (0.728–2.011)           | 0.461 |
| Multifocality* | 1.073 (0.662–1.740)   | 0.776                          | 1.181 (0.711–1.963)           | 0.520 |
| Intermediate risk versus high risk | | | | |
| ps-Tg* | 9.490 (5.733–15.707)           | \(< 0.001 \)                    | 8.021 (4.771–13.486)          | \(< 0.001 \) |
| Gender | 1.014 (0.725–1.419)            | 0.934                          | 0.962 (0.654–1.415)           | 0.843 |
| Age*   | 1.865 (1.347–2.583)            | \(< 0.001 \)                    | 2.239 (1.546–3.242)           | \(< 0.001 \) |
| Tumor size* | 3.141 (2.222–4.440)      | \(< 0.001 \)                    | 2.620 (1.785–3.846)           | \(< 0.001 \) |
| Multifocality* | 1.113 (0.808–1.532)   | 0.513                          | 1.156 (0.804–1.661)           | 0.434 |
| M0 versus M1 in high-risk | | | | |
| ps-Tg* | 31.161 (16.805–57.784)         | \(< 0.001 \)                    | 31.977 (16.575–61.688)        | \(< 0.001 \) |
| Gender | 1.663 (1.039–2.661)            | 0.034                          | 1.667 (0.858–3.237)           | 0.131 |
| Age*   | 1.162 (0.741–1.822)            | 0.513                          | 1.603 (0.831–3.090)           | 0.159 |
| Tumor size* | 4.677 (2.300–9.510)       | \(< 0.001 \)                    | 5.225 (2.055–13.281)          | \(< 0.001 \) |
| Multifocality* | 1.008 (0.641–1.585)   | 0.971                          | 0.777 (0.405–1.492)           | 0.449 |
| M0 versus M1 in all patients | | | | |
| ps-Tg* | 57.916 (33.125–101.260)        | \(< 0.001 \)                    | 52.141 (28.581–95.122)        | \(< 0.001 \) |
| Gender | 1.623 (1.079–2.442)            | 0.020                          | 1.611 (0.878–2.958)           | 0.124 |
| Age*   | 1.471 (0.988–2.190)            | 0.057                          | 2.670 (1.441–4.946)           | 0.002 |
| Tumor size* | 8.089 (4.146–15.780)       | \(< 0.001 \)                    | 6.384 (2.770–14.713)          | \(< 0.001 \) |
| Multifocality* | 1.088 (0.730–1.622)   | 0.679                          | 0.886 (0.492–1.596)           | 0.687 |

*The cut-off values for ps-Tg based status dichotomy were 2.95 ng/ml, 29.5 ng/ml, 47.1 ng/ml and 47.1 ng/ml while distinguishing between low-risk and intermediate-risk, intermediate-risk and high-risk, without and with distant metastasis in the high-risk group, and without and with distant metastasis in all patients; †The dichotomy values were age 45 years, 1 cm and one lesion for age, tumor size and multifocality, respectively. M0: No distant metastasis; M1: Distant metastasis; CI: Confidence interval; OR: Odds ratio; ps-Tg: Preablative stimulated thyroglobulin.

Analysis of preablative stimulated thyroglobulin thyroid stimulating hormone

The parameter Ps-Tg/TSH displayed similar trends to the ps-Tg in value comparisons and ROC analysis [Table 2 and Figure 2], implying that both the thyroid remnant and TSH had little influence on the ps-Tg level in this study.

Patients with distant metastasis

As stated above, the cut-off ps-Tg value of 47.1 ng/ml was found to be a good predictive index in discriminating the M1 from M0 subgroup. Utilizing this cut-off value, 10.26% of patients could be identified before radiiodine treatment as M1 patients in this study, without any other evidence of distant metastasis; however, they were finally confirmed to harbor distant metastases using imaging involving RxWBS after radiiodine treatment [Table 4]. Hence, the ps-Tg level could be the only evidence available for those patients who would benefit from modified high-dose radiiodine treatment based upon ongoing preablative reassessment.

Discussion

Previous studies have suggested that the predictive value of ps-Tg regarding both the success of ablation and prognosis was highly informative. One study showed that the 10-year...
Table 4: Evidence of distant metastasis in patients in the M1 subgroup (n = 117)

| CT* | ps-Tg ≥47.1 ng/ml | RxWBS* | Patient number (%) |
|-----|-------------------|--------|--------------------|
| (−) | (+)               | (+)    | 12 (10.26)         |
| (−) | (−)               | (+)    | 7 (5.98)           |
| (+) | (+)               | (−)    | 5 (4.27)           |
| (+) | (−)               | (+)    | 4 (3.42)           |
| (+) | (+)               | (−)    | 83 (70.94)         |
| (+) | (−)               | (+)    | 6 (5.13)           |

*Finding of distant metastatic lesions is defined as (+), and finding of no distant metastatic lesions is defined as (−) in the first and the third column; ‘ps-Tg ≥47.1 ng/ml is defined as (+), and ps-Tg <47.1 ng/ml is defined as (−) in the second column; ‘Three patients suffered from both pulmonary and bone metastases confirmed by both RxWBS and bone scintigraphy. M1: Distant metastasis; CT: Computed tomography; RxWBS: Postradiiodine-therapy whole-body scanning; ps-Tg: Preablative stimulated thyroglobulin.

In the present study, we considered ps-Tg as one of the ongoing postoperative reassessment factors, correlating the ps-Tg level with the newly developed recurrence risk staging system, and provided relevant data from Chinese patients. Our findings suggested that a higher ps-Tg level indicated a more advanced stage of recurrence risk. Significant differences in ps-Tg levels have been found both among the three recurrence risk groups and between each two pairwise groups, indicating a remarkable difference in ps-Tg levels in different recurrence risk groups. ROC analysis was conducted to define a certain cut-off value between each two pairwise groups. Logistic analysis was also used to determine the OR values in verifying if ps-Tg could be regarded as an independent predictive factor regarding the risk of recurrence. Two definite cut-off values for ps-Tg level, 2.95 ng/ml and 29.5 ng/ml, were obtained for differentiating between the L and I and between the I and H groups, respectively; these cut-off values might be candidate indicators for different recurrence risk stratifications. In addition, in the H group, we found that the ps-Tg cut-off value (47.1 ng/ml) had a high sensitivity and specificity in distinguishing patients with distant metastasis from those with no metastasis. In addition, a high specificity (93.7%) and remarkably high OR (42.492) regarding the ps-Tg cut-off value (47.1 ng/ml) have been identified while discriminating distant metastasis in all patients; this finding might offer a specific cut-off value to further determine distant metastasis in high-risk patients in the absence of additional preablative metastatic evidence. Although the ps-Tg level has shown relatively lower accuracy in distinguishing both the L from the I and the I from the H groups relative to that achieved in differentiating the M1 from M0 subgroup, it still has a meaningful predictive value with OR values of 2.712 and 31.801, respectively. All of these results indicated that the ps-Tg level might be an independent postoperative assessment factor and provide ongoing serologic evidence for the recurrence risk stratification system.

In addition, from our findings, it is noteworthy that ps-Tg might be the only indicator available for the identification of distant metastases, and thus if measured prior to radioiodine therapy would prevent 10.26% of patients with M1 from undertreatment. Therefore, the ps-Tg level could be used in conjunction with other ATA recurrence risk stratification indexes to improve the prediction of recurrence risk and dictate the most appropriate therapy.

As it is well-established, TSH can stimulate Tg release from the residual thyroid tissue or metastatic carcinoma tissue, indicating that Tg release is TSH-dependent. Consequently, we took TSH as a correction factor, and the ps-Tg/TSH parameter was used in the present study to exclude the influence of postsurgical residual thyroid tissue. Similar results were obtained using ps-Tg/TSH and ps-Tg, both in the comparison of different recurrence risk groups and in the ROC analyses; this reflected the fact that TSH had no significant influence on ps-Tg in the current study and also suggested that the patients had undergone complete thyroid resection.
A limitation of our study was that the follow-up outcomes were not available. Further studies are warranted to follow-up patients in the three risk recurrence categories after total thyroidectomy and radioiodine treatment. In addition, therapy response would need to be evaluated by means of physical examination, neck ultrasound scans, imaging and Tg serial values.

In summary, the ps-Tg level was found to be related to the risk of recurrence, and the corresponding cut-off value was obtained for discriminating different risks of recurrence with meaningful ORs and relatively high specificity. Ps-Tg could be considered as a convenient and reliable ongoing marker in indicating different risks of recurrence. It might be the only indicator that can be used to identify distant metastases, and thus if measured before radioiodine therapy would prevent more than 10% of patients with M1 from undertreatment. In addition, it could provide incremental value for both recurrence risk stratification and radioiodine decision-making.

**REFERENCES**

1. Hundahl SA, Fleming ID, Frengen AM, Meenck HR. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S 1985-1995. Cancer 1998;83:2638-48.
2. Rossi RL, Majlis S, Rossi RM. Thyroid cancer. Surg Clin North Am 2000;80:571-80.
3. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994;97:418-28.
4. Samaan NA, Schultz PN, Hickey RC, Goepfert H, Haynie TP, Johnston DA, et al. The results of various modalities of treatment of well differentiated thyroid carcinomas: A retrospective review of 1599 patients. J Clin Endocrinol Metab 1992;75:714-20.
5. Tuttle RM, Lebeouf R. Follow up approaches in thyroid cancer: A risk adapted paradigm. Endocrinol Metab Clin North Am 2008;37:419-35, ix.
6. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009;19:1167-214.
7. Tuttle RM, Tala H, Shah J, Lebeouf R, Ghossein R, Gonen M, et al. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: Using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid 2010;20:1341-9.
8. Ruiz-Garcia J, Ruiz de Almodóvar JM, Olea N, Pedraza V. Thyroglobulin level as a predictive factor of tumoral recurrence in differentiated thyroid cancer. J Nucl Med 1991;32:395-8.
9. Webb RC, Howard RS, Stojadinovic A, Gaitonde DY, Wallace MK, Ahmed J, et al. The utility of serum thyroglobulin measurement at the time of remnant ablation for predicting disease-free status in patients with differentiated thyroid cancer: A meta-analysis involving 3947 patients. J Clin Endocrinol Metab 2012;97:2754-63.
10. Kondiler DB, Vaisman F, Corbo R, Martins R, Vaisman M. Preablation stimulated thyroglobulin is a good predictor of successful ablation in patients with differentiated thyroid cancer. Clin Nucl Med 2012;37:545-9.
11. Mazzaferri EL, Robbins RJ, Spencer CA, Braverman LE, Pacini F, Wartofsky L, et al. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 2003;88:1433-41.
12. Cailloux AF, Baudin E, Travagl JP, Ricard M, Schlumberger M. Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer? J Clin Endocrinol Metab 2000;85:175-8.
13. Padovani RP, Robenshtok E, Brokhin M, Tuttle RM. Even without additional therapy, serum thyroglobulin concentrations often decline for years after total thyroidectomy and radioactive remnant ablation in patients with differentiated thyroid cancer. Thyroid 2012;22:778-83.
14. Pitoia F, Abelleira E, Tala H, Bueno F, Urciuoli C, Gross G. Biochemical persistence in thyroid cancer: Is there anything to worry about? Endocrine 2014;46:532-7.
15. Miyauchi A, Kudo T, Miya A, Kobayashi K, Ito Y, Takamura Y, et al. Prognostic impact of serum thyroglobulin doubling-time under thyrotropin suppression in patients with papillary thyroid carcinoma who underwent total thyroidectomy. Thyroid 2011;21:707-16.
16. Spencer CA, Takeuchi M, Kazarosyan M, Wang CC, Guttler RB, Singer PA, et al. Serum thyroglobulin autoantibodies: Prevalence, influence on serum thyroglobulin measurement, and prognostic significance in patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 1998;83:1121-7.
17. The NCCN Thyroid Carcinoma Clinical Practice Guidelines in Oncology. Version 2; 01 Aug, 2012. Available from: [Last accessed on 2014 Nov 10].
18. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines Taskforce. Thyroid 2006;16:109-42.
19. The NCCN Thyroid Carcinoma Clinical Practice Guidelines in Oncology. Version 2; 06 Aug, 2007. Available from: [Last accessed on 2014 Nov 10].
20. Guimarães V, DeGroot LJ. Moderate hypothyroidism in preparation for whole body 131I scintiscans and thyroglobulin testing. Thyroid 1996;6:69-73.
21. Spencer CA, LoPresti JS, Fatemis S, Nicoloff JT. Detection of residual and recurrent differentiated thyroid carcinoma by serum thyroglobulin measurement. Thyroid 1999;9:435-41.
22. Schlumberger M, Baudin E. Serum thyroglobulin determination in the follow-up of patients with differentiated thyroid carcinoma. Eur J Endocrinol 1998;138:249-52.
23. Heemstra KA, Liu YS, Stokkel M, Kiveit J, Corssmit E, Pereira AM, et al. Serum thyroglobulin concentrations predict disease-free remission and death in differentiated thyroid carcinoma. Clin Endocrinol (Oxf) 2007;66:58-64.
24. Lee HJ, Rha SY, Jo YS, Kim SM, Ku BJ, Shong M, et al. Predictive value of the preablation serum thyroglobulin level after thyroidectomy is combined with postablation 131I whole body scintigraphy for successful ablation in patients with differentiated thyroid carcinoma. Am J Clin Oncol 2007;30:63-8.
25. Lin Y, Li T, Liang J, Li X, Qiu L, Wang S, et al. Predictive value of preablation stimulated thyroglobulin and thyroglobulin/thyroid-stimulating hormone ratio in differentiated thyroid cancer. Clin Nucl Med 2011;36:1102-5.
26. Li T, Lin Y, Liang J, Li X, Qiu L, Wang S, et al. Predictive value of pre-ablation stimulated Tg in distant metastasis of papillary thyroid cancer (in Chinese). Chin J Nucl Med Mol Imaging 2012;32:189-91.
27. Teng WP, Liu YF, Gao M, Huang G, Wu Y, Zhao JJ, et al. Chinese management guidelines for patients with thyroid nodules and differentiated thyroid cancer (in Chinese). Chin J Endocrinol Metab 2012;28:779-97.